+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biosimilars And Biosuperiors Market Research Reports

Bevacizumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Bevacizumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 125 Pages
  • Global
From
Somatotropin - Biosimilar Insight, 2022 - Product Thumbnail Image

Somatotropin - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 70 Pages
  • Global
From
Infliximab-Biosimilars Insight, 2022 - Product Thumbnail Image

Infliximab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
Ranibizumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Ranibizumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 150 Pages
  • Global
From
Rituximab-Biosimilars Insight, 2022 - Product Thumbnail Image

Rituximab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 125 Pages
  • Global
From
Adalimumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Adalimumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
Trastuzumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Trastuzumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 125 Pages
  • Global
From
Insulin Glargine- - Biosimilar Insight, 2022 - Product Thumbnail Image

Insulin Glargine- - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
Filgrastim - Biosimilar Insight, 2022 - Product Thumbnail Image

Filgrastim - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 70 Pages
  • Global
From
Darbepoetin alfa- Biosimilar Insight, 2022 - Product Thumbnail Image

Darbepoetin alfa- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Epoetin alfa- Biosimilar Insight, 2022 - Product Thumbnail Image

Epoetin alfa- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Follitropin alfa- Biosimilar Insight, 2022 - Product Thumbnail Image

Follitropin alfa- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Pegfilgrastim- Biosimilar Insight, 2022 - Product Thumbnail Image

Pegfilgrastim- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Teriparatide- Biosimilar Insight, 2022 - Product Thumbnail Image

Teriparatide- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Europe Biosimilar Market Report and Forecast 2023-2028 - Product Thumbnail Image

Europe Biosimilar Market Report and Forecast 2023-2028

  • Report
  • October 2023
  • 158 Pages
  • Europe
From
From
Biosimilars Market Report and Forecast 2023-2031 - Product Thumbnail Image

Biosimilars Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
Rituximab Biosimilars Market Report and Forecast 2023-2031 - Product Thumbnail Image

Rituximab Biosimilars Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
From
Biosimilar Market Report and Forecast 2021-2026 - Product Thumbnail Image

Biosimilar Market Report and Forecast 2021-2026

  • Report
  • October 2021
  • 241 Pages
  • Global
From
Loading Indicator

The Biosimilars and Biosuperiors market is a rapidly growing sector of the pharmaceutical industry. Biosimilars are biologic drugs that are highly similar to an existing biologic drug, while biosuperiors are biologic drugs that are more effective than an existing biologic drug. Biosimilars and biosuperiors are used to treat a variety of conditions, including cancer, autoimmune diseases, and inflammatory diseases. Biosimilars and biosuperiors are developed using advanced biotechnology techniques, such as recombinant DNA technology and monoclonal antibody technology. These drugs are designed to be more cost-effective than their original counterparts, while still providing the same therapeutic benefits. The Biosimilars and Biosuperiors market is expected to continue to grow in the coming years, as more biologic drugs are developed and approved for use. Companies in this market include Amgen, Pfizer, Merck, and Novartis. Show Less Read more